White Paper

The Race To Phase III: A Cautionary Tale Of Scalability

By Anil Kane, Ph.D., Executive Director and Global Head of Technical & Scientific Affairs, Pharma Services, Thermo Fisher Scientific

The Race to Phase III: A Cautionary Tale of Scalability

As drug products move from preclinical through Phase IV development stages, clinical material demand grows tremendously. Production scale-up is rarely straightforward. Scaling up drug product manufacturing often requires time-consuming, expensive and unexpected challenge resolution.

How can firms mitigate risks and make scalability as smooth as possible? In this representative example, we follow the paths of two companies facing this challenge as they learn how a science-led, risk-based development approach yields a more successful outcome in the long run.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Outsourced Pharma? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: